Key terms
About HOOK
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HOOK news
Yesterday
7:31am ET
Truist Financial Remains a Buy on Hookipa Pharma (HOOK)
Yesterday
6:20am ET
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Apr 25
7:22am ET
Hookipa Pharma Announces Major HB-200 Clinical Trial Design
Apr 24
2:45pm ET
Buy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic Advancements
Apr 24
7:09am ET
Hookipa Pharma announces FDA clearance of IND application for HB-700
Mar 25
6:30am ET
Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), Hookipa Pharma (HOOK) and Sagimet Biosciences, Inc. Class A (SGMT)
Mar 24
9:48pm ET
Hookipa Pharma (HOOK) Receives a Buy from RBC Capital
Mar 22
11:55am ET
Buy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease Pipelines
Mar 22
7:06am ET
Hookipa Pharma reports Q4 EPS (22c), consensus (19c)
Feb 01
12:07am ET
Maintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline Promise
Jan 29
11:35am ET
Strategic Focus on Promising HPV+ Cancer Candidate Underpins Buy Rating for Hookipa Pharma
HOOK Financials
Key terms
Ad Feedback
HOOK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HOOK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range